These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21048284)

  • 1. The future of erectile dysfunction (ED).
    Porst H
    Arch Esp Urol; 2010 Oct; 63(8):740-7. PubMed ID: 21048284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].
    Sperling H; Lümmen G; Schneider T; Rübben H
    Herz; 2003 Jun; 28(4):314-24. PubMed ID: 12825147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ; Gales MA
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy and erectile dysfunction: the current status.
    Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH
    Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
    Zhang SX; Gao P
    Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC; McKenna KE
    Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Berner MM; Kriston L; Harms A
    Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
    Porst H
    Urologe A; 2004 Jul; 43(7):820-8. PubMed ID: 15197447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Firoozi F; Longhurst PA; White MD
    BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
    Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
    Chen Q; Wang N; Yao F; Lu X
    Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
    Zumbé J; Porst H; Sommer F; Grohmann W; Beneke M; Ulbrich E
    Eur Urol; 2008 Jul; 54(1):204-10. PubMed ID: 18395326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra).
    Montorsi F; Padma-Nathan H; Glina S
    Urology; 2006 Sep; 68(3 Suppl):26-37. PubMed ID: 17011373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for erectile dysfunction: fact or fiction?
    Kendirci M; Teloken PE; Champion HC; Hellstrom WJ; Bivalacqua TJ
    Eur Urol; 2006 Dec; 50(6):1208-22. PubMed ID: 16950560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.